BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 15945344)

  • 1. Practical management of chemotherapy-induced nausea and vomiting.
    Wiser W; Berger A
    Oncology (Williston Park); 2005 Apr; 19(5):637-45. PubMed ID: 15945344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced nausea and vomiting.
    Lohr L
    Cancer J; 2008; 14(2):85-93. PubMed ID: 18391612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
    Slatkin NE
    J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use.
    Wickham R
    J Support Oncol; 2010; 8(2 Suppl 1):10-5. PubMed ID: 20629453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes.
    Hawkins R; Grunberg S
    Clin J Oncol Nurs; 2009 Feb; 13(1):54-64. PubMed ID: 19193549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
    Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
    J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the prevention and management of CINV.
    Natale JJ
    Am J Manag Care; 2018 Oct; 24(18 Suppl):S391-S397. PubMed ID: 30328690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of chemotherapy-induced nausea and vomiting(CINV)using MASCC antiemesis tool].
    Yamaguchi M; Ogawa T; Watanabe M; Anami S; Kamigaki S; Nishikawa N; Ono T; Furukawa H
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1691-6. PubMed ID: 19838029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
    Durand JP; Madelaine I; Scotté F
    Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
    Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment--how are we doing?
    Grunberg SM
    J Support Oncol; 2004; 2(1 Suppl 1):1-10, inside back cover; quiz 11. PubMed ID: 16117016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting.
    Schwartzberg LS; Grunberg SM; Kris MG
    Clin Adv Hematol Oncol; 2011 Nov; 9(11 Suppl 27):1-14; quiz 15-6. PubMed ID: 22362372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy induced emesis: pathophysiology and prevention].
    Mailliez A; Bonneterre J
    Bull Cancer; 2010 Feb; 97(2):233-43. PubMed ID: 20051348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed Chemotherapy-Induced Nausea and Vomiting in the Hematology Population: A Review of the Literature.
    Gonella S; Di Giulio P
    Clin J Oncol Nurs; 2015 Aug; 19(4):438-43. PubMed ID: 26207708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children.
    Dupuis LL; Nathan PC
    Paediatr Drugs; 2003; 5(9):597-613. PubMed ID: 12956617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
    Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F
    Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.